Showing results (71-80 of 133) with videos related to

Sort By:
Pageof 14
NPJ Breast Cancer|April 17, 2021
TERT promoter hotspot mutations and gene amplification in metaplastic breast cancerEdaise M da Silva, Pier Selenica, Mahsa Vahdatinia, et al.
Genome Medicine|August 28, 2024
Large-scale copy number alterations are enriched for synthetic viability in BRCA1/BRCA2 tumorsYingjie Zhu, Xin Pei, Ardijana Novaj, et al.
Nature Communications|September 5, 2024
RAD52 resolves transcription-replication conflicts to mitigate R-loop induced genome instabilityManisha Jalan, Aman Sharma, Xin Pei, et al.
Cancer Cell|December 12, 2018
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo PathwayZhiqiang Li, Pedram Razavi, Qing Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 23, 2024
Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutationsOsama Shiraz Shah, Azadeh Nasrazadani, Julia Foldi, et al.
The Journal of Pathology|November 18, 2017
MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion geneJisun Kim, Felipe C Geyer, Luciano G Martelotto, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Spatial molecular profiling of mixed invasive ductal-lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutationsOsama Shiraz Shah, Azadeh Nasrazadani, Julia Foldi, et al.
Gynecologic Oncology Reports|August 4, 2021
Pattern of disease and response to pembrolizumab in recurrent cervical cancerKathryn M Miller, Olga T Filippova, Sara A Hayes, et al.
Gynecologic Oncology|May 28, 2023
Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinomaEric Rios-Doria, Amir Momeni-Boroujeni, Claire F Friedman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial CancerAngela K Green, Qin Zhou, Alexia Iasonos, et al.
Pageof 14